Belinda Yeo

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer

Sheau Wen Lok, James R. Whittle, François Vaillant et al. · Cancer Discovery · 2019 · 145 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

The prognostic effects of somatic mutations in ER-positive breast cancer

Obi L. Griffith, Nicholas C. Spies, Meenakshi Anurag et al. · Nature Communications · 2018 · 143 citations · Full text

Medicine, Genetics, Oncology +17

Tumor microenvironmental cytokines bound to cancer exosomes determine uptake by cytokine receptor-expressing cells and biodistribution

Luize G. Lima, Sunyoung Ham, Hyunku Shin et al. · Nature Communications · 2021 · 139 citations · Full text

Medicine, Cancer Biology, Oncology +17

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

David Miles, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2021 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17